Literature DB >> 16481904

Influence of human serum albumin on longitudinal and transverse relaxation rates (r1 and r2) of magnetic resonance contrast agents.

Frederik L Giesel1, Hendrik von Tengg-Kobligk, Iain D Wilkinson, Peter Siegler, Claus-W von der Lieth, Martin Frank, Klaus P Lodemann, Marco Essig.   

Abstract

OBJECTIVES: Exogenous magnetic resonance (MR) contrast media (CM) are used to improve detection and delineation of physiological and pathologic structures. Temporary binding between CM and proteins such as human serum albumin (HSA) may alter the relaxation-enhancing properties of specific contrast agents. In this study, the presence and strength of HSA interaction with different CM was investigated.
MATERIAL AND METHODS: Three contrast agents were chosen: Gd-DTPA, Gd-BT-DO3A, and Gd-BOPTA, each of which is known to have a different protein interaction. Samples were prepared using 7 different HSA concentrations, all at a constant CM concentration of 0.5 mmol/L. The relaxation rates, R1 and R2, of each sample were measured at 1.5 T. Virtual docking studies were performed to estimate the number of high affinity-binding sites of Gd-BOPTA and the surface of the HSA dimer.
RESULTS: Gd-BOPTA caused the greatest increase in R1 and R2, which followed an exponential dependency with increasing HSA concentration. Between the range of 0 and 7 g/dL of HSA, Gd-DTPA and Gd-BT-DO3A showed a relative change in both relaxation rates of approximately 13% and 22% for R1 and 26% and 30% for R2, respectively. In contrast, Gd-BOPTA demonstrated a relative increase of approximately 108% and 363% for R1 and R2, respectively. Changes of HSA concentration within physiological range (3.5-5.5 g/dL) resulted in an increase of R1 and R2 of approximately 40% when using Gd-BOPTA. The docking study revealed that approximately 10 small hydrophobic pockets exist on the HSA surface where the aromatic tail of Gd-BOPTA can fit in and a stronger noncovalent binding can occur compared with Gd-DTPA and Gd-BT-DO3A.
CONCLUSION: Relaxation rates of Gd-BOPTA showed a strong dependency on HSA. In contrast, Gd-DTPA and Gd-BT-DO3A demonstrated little or no relevant dependency. On the basis of these results, the influence of serum protein concentration should be considered in both research studies and in clinical use.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16481904     DOI: 10.1097/01.rli.0000192421.81037.d5

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  25 in total

1.  Malignant focal liver lesions at contrast-enhanced ultrasonography and magnetic resonance with hepatospecific contrast agent.

Authors:  M D'Onofrio; S Crosara; R De Robertis; S Canestrini; V Cantisani; G Morana; R Pozzi Mucelli
Journal:  Ultrasound       Date:  2013-12-13

2.  In Vivo MR Imaging of Fibrin in a Neuroblastoma Tumor Model by Means of a Targeting Gd-Containing Peptide.

Authors:  L Chaabane; L Tei; L Miragoli; L Lattuada; M von Wronski; F Uggeri; V Lorusso; S Aime
Journal:  Mol Imaging Biol       Date:  2015-12       Impact factor: 3.488

Review 3.  Gadolinium contrast agents for CNS imaging: current concepts and clinical evidence.

Authors:  E Kanal; K Maravilla; H A Rowley
Journal:  AJNR Am J Neuroradiol       Date:  2014-05-22       Impact factor: 3.825

4.  Contrast-enhanced MR imaging of brain lesions: a large-scale intraindividual crossover comparison of gadobenate dimeglumine versus gadodiamide.

Authors:  H A Rowley; G Scialfa; P-y Gao; J A Maldjian; D Hassell; M J Kuhn; F J Wippold; M Gallucci; B C Bowen; I M Schmalfuss; J Ruscalleda; S Bastianello; C Colosimo
Journal:  AJNR Am J Neuroradiol       Date:  2008-07-03       Impact factor: 3.825

5.  Does higher gadolinium concentration play a role in the morphologic assessment of brain tumors? Results of a multicenter intraindividual crossover comparison of gadobutrol versus gadobenate dimeglumine (the MERIT Study).

Authors:  Z Seidl; J Vymazal; M Mechl; M Goyal; M Herman; C Colosimo; M Pasowicz; R Yeung; B Paraniak-Gieszczyk; B Yemen; N Anzalone; A Citterio; G Schneider; S Bastianello; J Ruscalleda
Journal:  AJNR Am J Neuroradiol       Date:  2012-03-01       Impact factor: 3.825

6.  Contrast-enhanced MR angiography: does a higher relaxivity MR contrast agent permit a reduction of the dose administered for routine vascular imaging applications?

Authors:  Xiaoying Xing; Xiangzhu Zeng; Xuan Li; Qiang Zhao; Miles A Kirchin; Gianpaolo Pirovano; Xiaoying Wang; Yuan Li; Roberto Iezzi; Francesco De Cobelli
Journal:  Radiol Med       Date:  2014-09-03       Impact factor: 3.469

Review 7.  High-relaxivity contrast-enhanced magnetic resonance neuroimaging: a review.

Authors:  Frederik L Giesel; Amit Mehndiratta; Marco Essig
Journal:  Eur Radiol       Date:  2010-06-23       Impact factor: 5.315

8.  Facile preparation of a new gadofullerene-based magnetic resonance imaging contrast agent with high 1H relaxivity.

Authors:  Chunying Shu; Frank D Corwin; Jianfei Zhang; Zhijian Chen; Jonathan E Reid; Minghao Sun; Wei Xu; Jae Hyun Sim; Chunru Wang; Panos P Fatouros; Alan R Esker; Harry W Gibson; Harry C Dorn
Journal:  Bioconjug Chem       Date:  2009-06       Impact factor: 4.774

9.  Comparison of gadobenate dimeglumine and gadodiamide in the evaluation of spinal vascular anatomy with MR angiography.

Authors:  M V Spampinato; S A Nguyen; Z Rumboldt
Journal:  AJNR Am J Neuroradiol       Date:  2010-01-06       Impact factor: 3.825

10.  Multicenter, intraindividual comparison of single-dose gadobenate dimeglumine and double-dose gadopentetate dimeglumine for MR angiography of the supra-aortic arteries (the Supra-Aortic VALUE study).

Authors:  Yanjun Li; X Li; D Li; J Lu; X Xing; F Yan; Yuan Li; X Wang; R Iezzi; F De Cobelli
Journal:  AJNR Am J Neuroradiol       Date:  2012-10-04       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.